24 results on '"Dilworth MR"'
Search Results
2. Human placental uptake of glutamine and glutamate is reduced in fetal growth restriction.
- Author
-
McIntyre KR, Vincent KMM, Hayward CE, Li X, Sibley CP, Desforges M, Greenwood SL, and Dilworth MR
- Subjects
- Adolescent, Adult, Amino Acid Transport System X-AG metabolism, Birth Weight, Female, Fetal Growth Retardation metabolism, Fetal Growth Retardation pathology, Gestational Age, Glutamic Acid analysis, Glutamine analysis, Humans, Infant, Newborn, Pregnancy, Pregnancy Proteins metabolism, TOR Serine-Threonine Kinases metabolism, Young Adult, Carbon Radioisotopes analysis, Fetal Development, Fetal Growth Retardation epidemiology, Glutamic Acid metabolism, Glutamine metabolism, Infant, Small for Gestational Age metabolism, Placenta metabolism
- Abstract
Fetal growth restriction (FGR) is a significant risk factor for stillbirth, neonatal complications and adulthood morbidity. Compared with those of appropriate weight for gestational age (AGA), FGR babies have smaller placentas with reduced activity of amino acid transporter systems A and L, thought to contribute to poor fetal growth. The amino acids glutamine and glutamate are essential for normal placental function and fetal development; whether transport of these is altered in FGR is unknown. We hypothesised that FGR is associated with reduced placental glutamine and glutamate transporter activity and expression, and propose the mammalian target of rapamycin (mTOR) signaling pathway as a candidate mechanism. FGR infants [individualised birth weight ratio (IBR) < 5th centile] had lighter placentas, reduced initial rate uptake of
14 C-glutamine and14 C-glutamate (per mg placental protein) but higher expression of key transporter proteins (glutamine: LAT1, LAT2, SNAT5, glutamate: EAAT1) versus AGA [IBR 20th-80th]. In further experiments, in vitro exposure to rapamycin inhibited placental glutamine and glutamate uptake (24 h, uncomplicated pregnancies) indicating a role of mTOR in regulating placental transport of these amino acids. These data support our hypothesis and suggest that abnormal glutamine and glutamate transporter activity is part of the spectrum of placental dysfunction in FGR.- Published
- 2020
- Full Text
- View/download PDF
3. A missense mutation of ErbB2 produces a novel mouse model of stillbirth associated with a cardiac abnormality but lacking abnormalities of placental structure.
- Author
-
Shawer H, Aiyelaagbe E, Clowes C, Lean SC, Lu Y, Kadler KE, Kerby A, Dilworth MR, Hentges KE, and Heazell AEP
- Subjects
- Animals, Disease Models, Animal, Female, Heart Block congenital, Heart Block genetics, Heart Block metabolism, Heart Block pathology, Heart Defects, Congenital metabolism, Heart Defects, Congenital pathology, Heterozygote, Homeobox Protein Nkx-2.5 genetics, Homozygote, Humans, Mice, Mice, Mutant Strains, Myocardium metabolism, Myocardium pathology, Placenta abnormalities, Placenta pathology, Pregnancy, RNA, Messenger genetics, RNA, Messenger metabolism, Heart Defects, Congenital genetics, Mutation, Missense, Receptor, ErbB-2 genetics, Stillbirth genetics
- Abstract
Background: In humans, stillbirth describes the death of a fetus before birth after 28 weeks gestation, and accounts for approximately 2.6 million deaths worldwide annually. In high-income countries, up to half of stillbirths have an unknown cause and are described as "unexplained stillbirths"; this lack of understanding impairs efforts to prevent stillbirth. There are also few animal models of stillbirth, but those that have been described usually have significant placental abnormalities. This study describes a novel mutant murine model of fetal death with atrial conduction block due to an ErbB2 missense mutation which is not associated with abnormal placental morphology., Methods: Phenotypic characterisation and histological analysis of the mutant mouse model was conducted. The mRNA distribution of the early cardiomyocyte marker Nkx2-5 was assessed via in situ hybridisation. Cardiac structure was quantified and cellular morphology evaluated by electron microscopy. Immunostaining was employed to quantify placental structure and cell characteristics on matched heterozygous and homozygous mutant placental samples., Results: There were no structural abnormalities observed in hearts of mutant embryos. Comparable Nkx2-5 expression was observed in hearts of mutants and controls, suggesting normal cardiac specification. Additionally, there was no significant difference in the weight, placenta dimensions, giant cell characteristics, labyrinth tissue composition, levels of apoptosis, proliferation or vascularisation between placentas of homozygous mutant mice and controls., Conclusion: Embryonic lethality in the ErbB2 homozygous mutant mouse cannot be attributed to placental pathology. As such, we conclude the ErbB2M802R mutant is a model of stillbirth with a non-placental cause of death. The mechanism of the atrial block resulting from ErbB2 mutation and its role in embryonic death is still unclear. Studying this mutant mouse model could identify candidate genes involved in stillbirth associated with structural or functional cardiac defects., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2020
- Full Text
- View/download PDF
4. Antenatal sildenafil citrate treatment increases offspring blood pressure in the placental-specific Igf2 knockout mouse model of FGR.
- Author
-
Renshall LJ, Cottrell EC, Cowley E, Sibley CP, Baker PN, Thorstensen EB, Greenwood SL, Wareing M, and Dilworth MR
- Subjects
- Animals, Birth Weight, Female, Fetal Growth Retardation genetics, Glucose Tolerance Test, Mice, Mice, Inbred C57BL, Mice, Knockout, Pregnancy, Prenatal Exposure Delayed Effects, Splanchnic Circulation drug effects, Vascular Resistance drug effects, Weight Gain drug effects, Blood Pressure drug effects, Fetal Growth Retardation drug therapy, Insulin-Like Growth Factor II genetics, Sildenafil Citrate therapeutic use, Vasodilator Agents therapeutic use
- Abstract
Fetal growth restriction (FGR), where a fetus fails to reach its genetic growth potential, affects up to 8% of pregnancies and is a major risk factor for stillbirth and adulthood morbidity. There are currently no treatments for FGR, but candidate therapies include the phosphodiesterase-5 inhibitor sildenafil citrate (SC). Randomized clinical trials in women demonstrated no effect of SC on fetal growth in cases of severe early onset FGR; however, long-term health outcomes on the offspring are unknown. This study aimed to assess the effect of antenatal SC treatment on metabolic and cardiovascular health in offspring by assessing postnatal weight gain, glucose tolerance, systolic blood pressure, and resistance artery function in a mouse model of FGR, the placental-specific insulin-like growth factor 2 (PO) knockout mouse. SC was administered subcutaneously (10 mg/kg) daily from embryonic day (E)12.5. Antenatal SC treatment did not alter fetal weight or viability but increased postnatal weight gain in wild-type (WT) female offspring ( P < 0.05) and reduced glucose sensitivity in both WT ( P < 0.01) and P0 ( P < 0.05) female offspring compared with controls. Antenatal SC treatment increased systolic blood pressure in both male (WT vs. WT-SC: 117 ± 2 vs. 140 ± 3 mmHg, P < 0.0001; P0 vs. P0-SC: 113 ± 3 vs. 140 ± 4 mmHg, P < 0.0001; means ± SE) and female (WT vs. WT-SC: 121 ± 2 vs. 140 ± 2 mmHg, P < 0.0001; P0 vs. P0-SC: 117 ± 2 vs. 144 ± 4 mmHg, P < 0.0001) offspring at 8 and 13 wk of age. Increased systolic blood pressure was not attributed to altered mesenteric artery function. In utero exposure to SC may result in metabolic dysfunction and elevated blood pressure in later life. NEW & NOTEWORTHY Sildenafil citrate (SC) is currently used to treat fetal growth restriction (FGR). We demonstrate that SC is ineffective at treating FGR, and leads to a substantial increase systolic blood pressure and alterations in glucose homeostasis in offspring. We therefore urge caution and suggest that further studies are required to assess the safety and efficacy of SC in utero, in addition to the implications on long-term health.
- Published
- 2020
- Full Text
- View/download PDF
5. Evidence of adaptation of maternofetal transport of glutamine relative to placental size in normal mice, and in those with fetal growth restriction.
- Author
-
McIntyre KR, Hayward CE, Sibley CP, Greenwood SL, and Dilworth MR
- Subjects
- Amino Acid Transport System X-AG genetics, Amino Acid Transport System X-AG metabolism, Animals, Biological Transport, Carbon Radioisotopes, Carrier Proteins genetics, Carrier Proteins metabolism, Female, Gene Expression Regulation, Genotype, Glutamic Acid metabolism, Insulin-Like Growth Factor II genetics, Insulin-Like Growth Factor II metabolism, Male, Mice, Mice, Inbred C57BL, Mice, Knockout, Pregnancy, Adaptation, Physiological, Fetal Growth Retardation physiopathology, Glutamine metabolism, Maternal-Fetal Exchange physiology, Placenta physiology
- Abstract
Key Points: Fetal growth restriction (FGR) is a major risk factor for stillbirth and has significant impact upon lifelong health. A small, poorly functioning placenta, as evidenced by reduced transport of nutrients to the baby, underpins FGR. It remains unclear how a small but normal placenta differs from the small FGR placenta in terms of ability to transfer nutrients to the fetus. Placental transport of glutamine and glutamate, key amino acids for fetal growth, was assessed in normal mice and those with FGR. Glutamine and glutamate transport was greater in the lightest versus heaviest placenta in a litter of normally grown mice. Placentas of mice with FGR had increased transport capacity in mid-pregnancy, but this adaptation was insufficient in late pregnancy. Placental adaptations, in terms of increased nutrient transport (per gram) to compensate for small size, appear to achieve appropriate fetal growth in normal pregnancy. Failure of this adaptation might contribute to FGR., Abstract: Fetal growth restriction (FGR), a major risk factor for stillbirth, and neonatal and adulthood morbidity, is associated with reduced placental size and decreased placental nutrient transport. In mice, a small, normal placenta increases its nutrient transport, thus compensating for its reduced size and maintaining normal fetal growth. Whether this adaptation occurs for glutamine and glutamate, two key amino acids for placental metabolism and fetal growth, is unknown. Additionally, an assessment of placental transport of glutamine and glutamate between FGR and normal pregnancy is currently lacking. We thus tested the hypothesis that the transport of glutamine and glutamate would be increased (per gram of tissue) in a small normal placenta [C57BL6/J (wild-type, WT) mice], but that this adaptation fails in the small dysfunctional placenta in FGR [insulin-like growth factor 2 knockout (P0) mouse model of FGR]. In WT mice, comparing the lightest versus heaviest placenta in a litter, unidirectional maternofetal clearance (K
mf ) of14 C-glutamine and14 C-glutamate (glutamine Kmf andglutamate Kmf ) was significantly higher at embryonic day (E) 18.5, in line with increased expression of LAT1, a glutamine transporter protein. In P0 mice,glutamine Kmf andglutamate Kmf were higher (P0 versus wild-type littermates, WTL) at E15.5. At E18.5,glutamine Kmf remained elevated whereasglutamate Kmf was similar between groups. In summary, we provide evidence thatglutamine Kmf andglutamate Kmf adapt according to placental size in WT mice. The placenta of the growth-restricted P0 fetus also elevates transport capacity to compensate for size at E15.5, but this adaptation is insufficient at E18.5; this may contribute to decreased fetal growth., (© 2019 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society.)- Published
- 2019
- Full Text
- View/download PDF
6. Mechanisms Underpinning Adaptations in Placental Calcium Transport in Normal Mice and Those With Fetal Growth Restriction.
- Author
-
Hayward CE, McIntyre KR, Sibley CP, Greenwood SL, and Dilworth MR
- Abstract
Fetal delivery of calcium, via the placenta, is crucial for appropriate skeletal mineralization. We have previously demonstrated that maternofetal calcium transport, per gram placenta, is increased in the placental specific insulin-like growth factor 2 knockout mouse (P0) model of fetal growth restriction (FGR) compared to wild type littermates (WTL). This effect was mirrored in wild-type (WT) mice comparing lightest vs. heaviest (LvH) placentas in a litter. In both models increased placental calcium transport was associated with normalization of fetal calcium content. Despite this adaptation being observed in small normal (WT), and small dysfunctional (P0) placentas, mechanisms underpinning these changes remain unknown. Parathyroid hormone-related protein (PTHrP), elevated in cord blood in FGR and known to stimulate plasma membrane calcium ATPase, might be important. We hypothesized that PTHrP expression would be increased in LvH WT placentas, and in P0 vs. WTL. We used calcium pathway-focused PCR arrays to assess whether mechanisms underpinning these adaptations in LvH WT placentas, and in P0 vs. WTL, were similar. PTHrP protein expression was not different between LvH WT placentas at E18.5 but trended toward increased expression (139%; P = 0.06) in P0 vs. WTL. PCR arrays demonstrated that four genes were differentially expressed in LvH WT placentas including increased expression of the calcium-binding protein calmodulin 1 (1.6-fold; P < 0.05). Twenty-four genes were differentially expressed in placentas of P0 vs. WTL; significant reductions were observed in expression of S100 calcium binding protein G (2-fold; P < 0.01), parathyroid hormone 1 receptor (1.7-fold; P < 0.01) and PTHrP (2-fold; P < 0.05), whilst serum/glucocorticoid-regulated kinase 1 (SGK1), a regulator of nutrient transporters, was increased (1.4 fold; P < 0.05). Tartrate resistant acid phosphatase 5 (TRAP5 encoded by Acp5) was reduced in placentas of both LvH WT and P0 vs. WTL (1.6- and 1.7-fold, respectively; P < 0.05). Signaling events underpinning adaptations in calcium transport are distinct between LvH placentas of WT mice and those in P0 vs. WTL. Calcium binding proteins appear important in functional adaptations in the former whilst PTHrP and SGK1 are also implicated in the latter. These data facilitate understanding of mechanisms underpinning placental calcium transport adaptation in normal and growth restricted fetuses.
- Published
- 2018
- Full Text
- View/download PDF
7. Melatonin Increases Fetal Weight in Wild-Type Mice but Not in Mouse Models of Fetal Growth Restriction.
- Author
-
Renshall LJ, Morgan HL, Moens H, Cansfield D, Finn-Sell SL, Tropea T, Cottrell EC, Greenwood S, Sibley CP, Wareing M, and Dilworth MR
- Abstract
Fetal growth restriction (FGR) presents with an increased risk of stillbirth and childhood and adulthood morbidity. Melatonin, a neurohormone and antioxidant, has been suggested as having therapeutic benefit in FGR. We tested the hypothesis that melatonin would increase fetal growth in two mouse models of FGR which together represent a spectrum of the placental phenotypes in this complication: namely the endothelial nitric oxide synthase knockout mouse (eNOS
-/- ) which presents with abnormal uteroplacental blood flow, and the placental specific Igf2 knockout mouse (P0+/- ) which demonstrates aberrant placental morphology akin to human FGR. Melatonin (5 μg/ml) was administered via drinking water from embryonic day (E)12.5 in C57Bl/6J wild-type (WT), eNOS-/- , and P0+/- mice. Melatonin supplementation significantly increased fetal weight in WT, but not eNOS-/- or P0+/- mice at E18.5. Melatonin did, however, significantly increase abdominal circumference in P0+/- mice. Melatonin had no effect on placental weight in any group. Uterine arteries from eNOS-/- mice demonstrated aberrant function compared with WT but melatonin treatment did not affect uterine artery vascular reactivity in either of these genotypes. Umbilical arteries from melatonin treated P0+/- mice demonstrated increased relaxation in response to the nitric oxide donor SNP compared with control. The increased fetal weight in WT mice and abdominal circumference in P0+/- , together with the lack of any effect in eNOS-/- , suggest that the presence of eNOS is required for the growth promoting effects of melatonin. This study supports further work on the possibility of melatonin as a treatment for FGR.- Published
- 2018
- Full Text
- View/download PDF
8. Pomegranate Juice Supplementation Alters Utero-Placental Vascular Function and Fetal Growth in the eNOS -/- Mouse Model of Fetal Growth Restriction.
- Author
-
Finn-Sell SL, Cottrell EC, Greenwood SL, Dilworth MR, Cowley EJ, Sibley CP, and Wareing M
- Abstract
The eNOS
-/- mouse provides a well-characterized model of fetal growth restriction (FGR) with altered uterine and umbilical artery function and reduced utero- and feto-placental blood flow. Pomegranate juice (PJ), which is rich in antioxidants and bioactive polyphenols, has been posited as a beneficial dietary supplement to promote cardiovascular health. We hypothesized that maternal supplementation with PJ will improve uterine and umbilical artery function and thereby enhance fetal growth in the eNOS-/- mouse model of FGR. Wild type (WT, C57Bl/6J) and eNOS-/- mice were supplemented from E12.5-18.5 with either PJ in their drinking water or water alone. At E18.5 uterine (UtA) and umbilical (UmbA) arteries were isolated for study of vascular function, fetuses and placentas were weighed and fetal biometric measurements taken. PJ supplementation significantly increased UtA basal tone (both genotypes) and enhanced phenylephrine-induced contraction in eNOS-/- but not WT mice. Conversely PJ significantly reduced UtA relaxation in response to both acetylcholine (Ach) and sodium nitroprusside (SNP), endothelium dependent and independent vasodilators respectively from WT but not eNOS-/- mice. UmbA sensitivity to U46619-mediated contraction was increased by PJ supplementation in WT mice; PJ enhanced contraction and relaxation of UmbA to Ach and SNP respectively in both genotypes. Contrary to our hypothesis, the changes in artery function induced by PJ were not associated with an increase in fetal weight. However, PJ supplementation reduced litter size and fetal abdominal and head circumference in both genotypes. Collectively the data do not support maternal PJ supplementation as a safe or effective treatment for FGR.- Published
- 2018
- Full Text
- View/download PDF
9. Adaptations in Maternofetal Calcium Transport in Relation to Placental Size and Fetal Sex in Mice.
- Author
-
Hayward CE, Renshall LJ, Sibley CP, Greenwood SL, and Dilworth MR
- Abstract
Appropriate placental transport of calcium is essential for normal fetal skeletal mineralization. In fetal growth restriction (FGR), the failure of a fetus to achieve its growth potential, a number of placental nutrient transport systems show reduced activity but, in the case of calcium, placental transport is increased. In a genetic mouse model of FGR this increase, or adaptation, maintains appropriate fetal calcium content, relative to the size of the fetus, despite a small, dysfunctional placenta. It is unknown whether such an adaptation is also apparent in small, but normally functioning placentas. We tested the hypothesis that calcium transfer would be up-regulated in the lightest vs. heaviest placentas in the same C57Bl/6J wild-type (WT) mouse litter. Since lightest placentas are often from females, we also assessed whether fetal sex influenced placental calcium transfer. Placentas and fetuses were collected at embryonic day (E)16.5 and 18.5; the lightest and heaviest placentas, and female and male fetuses, were identified. Unidirectional maternofetal calcium clearance (
Ca Kmf ) was assessed following45 Ca administration to the dam and subsequent radiolabel counts within the fetuses. Placental expression of calcium pathway components was measured by Western blot. Data (median) are lightest placenta expressed as percentage of the heaviest within a litter and analyzed by Wilcoxon signed-rank test. In WT mice having normally grown fetuses,Ca Kmf , per gram placenta near term, in the lightest placentas was increased (126%; P < 0.05) in association with reduced fetal calcium accretion earlier in gestation (92%; P < 0.05), that was subsequently normalized near term. Increased placental expression of calbindin-D9K , an important calcium binding protein, was observed in the lightest placentas near term (122%; P < 0.01). There was no difference in fetal calcium accretion between male and female littermates but a trend toward higherCa Kmf in females ( P = 0.055). These data suggest a small, normal placenta adapts calcium transfer according to its size, as previously demonstrated in a mouse model of FGR. Fetal sex had limited influence on this adaptive increase. These adaptations are potentially driven by fetal nutrient demand, as evidenced by the normalization of fetal calcium content. Understanding the regulatory mechanisms involved may provide novel avenues for treating placental dysfunction.- Published
- 2017
- Full Text
- View/download PDF
10. PTHrP is essential for normal morphogenetic and functional development of the murine placenta.
- Author
-
Duval C, Dilworth MR, Tunster SJ, Kimber SJ, and Glazier JD
- Subjects
- Animals, Female, Mice, Mice, Knockout, Placenta embryology, Placenta physiology, Pregnancy, Signal Transduction, Parathyroid Hormone-Related Protein metabolism, Parathyroid Hormone-Related Protein physiology, Placentation physiology
- Published
- 2017
- Full Text
- View/download PDF
11. Placental Dysfunction Underlies Increased Risk of Fetal Growth Restriction and Stillbirth in Advanced Maternal Age Women.
- Author
-
Lean SC, Heazell AEP, Dilworth MR, Mills TA, and Jones RL
- Subjects
- Adult, Animals, Female, Humans, Mice, Middle Aged, Models, Animal, Pregnancy, Young Adult, Fetal Growth Retardation epidemiology, Fetal Growth Retardation physiopathology, Maternal Age, Placenta pathology, Stillbirth epidemiology
- Abstract
Pregnancies in women of advanced maternal age (AMA) are susceptible to fetal growth restriction (FGR) and stillbirth. We hypothesised that maternal ageing is associated with utero-placental dysfunction, predisposing to adverse fetal outcomes. Women of AMA (≥35 years) and young controls (20-30 years) with uncomplicated pregnancies were studied. Placentas from AMA women exhibited increased syncytial nuclear aggregates and decreased proliferation, and had increased amino acid transporter activity. Chorionic plate and myometrial artery relaxation was increased compared to controls. AMA was associated with lower maternal serum PAPP-A and sFlt and a higher PlGF:sFlt ratio. AMA mice (38-41 weeks) at E17.5 had fewer pups, more late fetal deaths, reduced fetal weight, increased placental weight and reduced fetal:placental weight ratio compared to 8-12 week controls. Maternofetal clearance of
14 C-MeAIB and3 H-taurine was reduced and uterine arteries showed increased relaxation. These studies identify reduced placental efficiency and altered placental function with AMA in women, with evidence of placental adaptations in normal pregnancies. The AMA mouse model complements the human studies, demonstrating high rates of adverse fetal outcomes and commonalities in placental phenotype. These findings highlight placental dysfunction as a potential mechanism for susceptibility to FGR and stillbirth with AMA.- Published
- 2017
- Full Text
- View/download PDF
12. Placental Adaptation: What Can We Learn from Birthweight:Placental Weight Ratio?
- Author
-
Hayward CE, Lean S, Sibley CP, Jones RL, Wareing M, Greenwood SL, and Dilworth MR
- Abstract
Appropriate fetal growth relies upon adequate placental nutrient transfer. Birthweight:placental weight ratio (BW:PW ratio) is often used as a proxy for placental efficiency, defined as the grams of fetus produced per gram placenta. An elevated BW:PW ratio in an appropriately grown fetus (small placenta) is assumed to be due to up-regulated placental nutrient transfer capacity i.e., a higher nutrient net flux per gram placenta. In fetal growth restriction (FGR), where a fetus fails to achieve its genetically pre-determined growth potential, placental weight and BW:PW ratio are often reduced which may indicate a placenta that fails to adapt its nutrient transfer capacity to compensate for its small size. This review considers the literature on BW:PW ratio in both large cohort studies of normal pregnancies and those studies offering insight into the relationship between BW:PW ratio and outcome measures including stillbirth, FGR, and subsequent postnatal consequences. The core of this review is the question of whether BW:PW ratio is truly indicative of altered placental efficiency, and whether changes in BW:PW ratio reflect those placentas which adapt their nutrient transfer according to their size. We consider this question using data from mice and humans, focusing upon studies that have measured the activity of the well characterized placental system A amino acid transporter, both in uncomplicated pregnancies and in FGR. Evidence suggests that BW:PW ratio is reduced both in FGR and in pregnancies resulting in a small for gestational age (SGA, birthweight < 10th centile) infant but this effect is more pronounced earlier in gestation (<28 weeks). In mice, there is a clear association between increased BW:PW ratio and increased placental system A activity. Additionally, there is good evidence in wild-type mice that small placentas upregulate placental nutrient transfer to prevent fetal undergrowth. In humans, this association between BW:PW ratio and placental system A activity is less clear and is worthy of further consideration, both in terms of system A and other placental nutrient transfer processes. This knowledge would help decide the value of measuring BW:PW ratio in terms of determining the risk of poor health outcomes, both in the neonatal period and long term.
- Published
- 2016
- Full Text
- View/download PDF
13. The impact of a human IGF-II analog ([Leu27]IGF-II) on fetal growth in a mouse model of fetal growth restriction.
- Author
-
Charnock JC, Dilworth MR, Aplin JD, Sibley CP, Westwood M, and Crocker IP
- Subjects
- Animals, Disease Models, Animal, Embryo, Mammalian, Female, Fetal Growth Retardation drug therapy, Humans, Insulin-Like Growth Factor II administration & dosage, Insulin-Like Growth Factor II genetics, Insulin-Like Growth Factor II pharmacology, Mice, Mice, Inbred C57BL, Mice, Knockout, Nitric Oxide Synthase Type III genetics, Pregnancy, Recombinant Proteins administration & dosage, Recombinant Proteins pharmacology, Fetal Development drug effects, Fetal Growth Retardation pathology, Insulin-Like Growth Factor II analogs & derivatives
- Abstract
Enhancing placental insulin-like growth factor (IGF) availability appears to be an attractive strategy for improving outcomes in fetal growth restriction (FGR). Our approach was the novel use of [Leu(27)]IGF-II, a human IGF-II analog that binds the IGF-II clearance receptor IGF-IIR in fetal growth-restricted (FGR) mice. We hypothesized that the impact of [Leu(27)]IGF-II infusion in C57BL/6J (wild-type) and endothelial nitric oxide synthase knockout (eNOS(-/-); FGR) mice would be to enhance fetal growth and investigated this from mid- to late gestation; 1 mg·kg(-1)·day(-1) [Leu(27)]IGF-II was delivered via a subcutaneous miniosmotic pump from E12.5 to E18.5. Fetal and placental weights recorded at E18.5 were used to generate frequency distribution curves; fetuses <5th centile were deemed growth restricted. Placentas were harvested for immunohistochemical analysis of the IGF system, and maternal serum was collected for measurement of exogenously administered IGF-II. In WT pregnancies, [Leu(27)]IGF-II treatment halved the number of FGR fetuses, reduced fetal(P = 0.028) and placental weight variations (P = 0.0032), and increased the numbers of pups close to the mean fetal weight (131 vs. 112 pups within 1 SD). Mixed-model analysis confirmed litter size to be negatively correlated with fetal and placental weight and showed that [Leu(27)]IGF-II preferentially improved fetal weight in the largest litters, as defined by number. Unidirectional (14C)MeAIB transfer per gram placenta (System A amino acid transporter activity) was inversely correlated with fetal weight in [Leu(27)]IGF-II-treated WT animals (P < 0.01). In eNOS(-/-) mice, [Leu(27)]IGF-II reduced the number of FGR fetuses(1 vs. 5 in the untreated group). The observed reduction in FGR pup numbers in both C57 and eNOS(-/-) litters suggests the use of this analog as a means of standardizing and rescuing fetal growth, preferentially in the smallest offspring., (Copyright © 2016 the American Physiological Society.)
- Published
- 2016
- Full Text
- View/download PDF
14. The maternal environment programs postnatal weight gain and glucose tolerance of male offspring, but placental and fetal growth are determined by fetal genotype in the Leprdb/+ model of gestational diabetes.
- Author
-
Nadif R, Dilworth MR, Sibley CP, Baker PN, Davidge ST, Gibson JM, Aplin JD, and Westwood M
- Subjects
- Animals, Female, Genotype, Male, Mice, Pregnancy, Receptors, Leptin genetics, Diabetes, Gestational metabolism, Fetal Development genetics, Glucose Intolerance genetics, Placentation, Receptors, Leptin metabolism, Weight Gain genetics
- Abstract
Mice heterozygous for a signaling-deficient leptin receptor (Leprdb/+ [db/+]) are widely used as a model of gestational diabetes that results in poor fetal outcomes. This study investigated the importance of fetal genotype (db/+) relative to abnormal maternal metabolism for placental function and therefore fetal growth and offspring health. Wild-type (WT) and db/+ females were mated to db/+ and WT males, respectively, generating litters of mixed genotype. Placentas and fetuses were weighed at embryonic day 18.5; offspring weight, hormone levels, glucose tolerance, and blood pressure were assessed at 3 and 6 months. Pregnant db/+, but not WT, dams had impaired glucose tolerance. The db/+ placentas and fetuses were heavier than WT, but the maternal environment had no effect; WT placentas/fetuses from db/+ mothers were no bigger than WT placentas/fetuses carried by WT mothers. Postnatal weight gain, glucose metabolism, and leptin levels were all influenced by offspring genotype. However, maternal environment affected aspects of offspring health because WT male offspring born to db/+ dams were heavier and had worse glucose tolerance than the sex-matched WT offspring of WT mothers. Blood pressure was not affected by maternal or offspring genotype. These data reveal that studies using the db/+ mouse to model outcomes of pregnancy complicated by gestational diabetes should be mindful of the genetically predisposed fetal/postnatal overgrowth. Although inappropriate for dissecting the effect of maternal hyperglycemia on the contribution of placental function to macrosomia, the db/+ mouse may prove useful for investigating mechanisms underlying programming of suboptimal postnatal weight gain and glucose metabolism by an adverse maternal metabolic environment.
- Published
- 2015
- Full Text
- View/download PDF
15. In vitro assessment of mouse fetal abdominal aortic vascular function.
- Author
-
Renshall LJ, Dilworth MR, Greenwood SL, Sibley CP, and Wareing M
- Subjects
- Animals, Aorta, Abdominal drug effects, Aorta, Abdominal embryology, Aorta, Abdominal metabolism, Disease Models, Animal, Dose-Response Relationship, Drug, Female, Fetal Growth Retardation genetics, Fetal Growth Retardation metabolism, Gestational Age, Insulin-Like Growth Factor II deficiency, Insulin-Like Growth Factor II genetics, Mice, Mice, Knockout, Phenotype, Phosphodiesterase 5 Inhibitors pharmacology, Piperazines pharmacology, Pregnancy, Purines pharmacology, Sildenafil Citrate, Sulfones pharmacology, Vasoconstriction, Vasoconstrictor Agents pharmacology, Vasodilation, Vasodilator Agents pharmacology, Aorta, Abdominal physiopathology, Fetal Growth Retardation physiopathology
- Abstract
Fetal growth restriction (FGR) affects 3-8% of human pregnancies. Mouse models have provided important etiological data on FGR; they permit the assessment of treatment strategies on the physiological function of both mother and her developing offspring. Our study aimed to 1) develop a method to assess vascular function in fetal mice and 2) as a proof of principle ascertain whether a high dose of sildenafil citrate (SC; Viagra) administered to the pregnant dam affected fetal vascular reactivity. We developed a wire myography methodology for evaluation of fetal vascular function in vitro using the placenta-specific insulin-like growth factor II (Igf2) knockout mouse (P0; a model of FGR). Vascular function was determined in abdominal aortas isolated from P0 and wild-type (WT) fetuses at embryonic day (E) 18.5 of gestation. A subset of dams received SC 0.8 mg/ml via drinking water from E12.5; data were compared with water-only controls. Using wire myography, we found that fetal aortic rings exhibited significant agonist-induced contraction, and endothelium-dependent and endothelium-independent relaxation. Sex-specific alterations in reactivity were noted in both strains. Maternal treatment with SC significantly attenuated endothelium-dependent and endothelium-independent relaxation of fetal aortic rings. Mouse fetal abdominal aortas reproducibly respond to vasoactive agents. Study of these vessels in mouse genetic models of pregnancy complications may 1) help to delineate early signs of abnormal vascular reactivity and 2) inform whether treatments given to the mother during pregnancy may impact upon fetal vascular function., (Copyright © 2014 the American Physiological Society.)
- Published
- 2014
- Full Text
- View/download PDF
16. Sildenafil citrate increases fetal weight in a mouse model of fetal growth restriction with a normal vascular phenotype.
- Author
-
Dilworth MR, Andersson I, Renshall LJ, Cowley E, Baker P, Greenwood S, Sibley CP, and Wareing M
- Subjects
- Animals, Blood Flow Velocity drug effects, Disease Models, Animal, Female, Fetal Growth Retardation metabolism, Fetus blood supply, Fetus metabolism, Humans, Insulin-Like Growth Factor II metabolism, Mice, Mice, Knockout, Phenotype, Phosphodiesterase Inhibitors pharmacology, Placenta blood supply, Placenta metabolism, Pregnancy, Purines pharmacology, Sildenafil Citrate, Umbilical Arteries metabolism, Fetal Development drug effects, Fetal Growth Retardation drug therapy, Fetal Weight drug effects, Fetus drug effects, Piperazines pharmacology, Sulfones pharmacology, Uterine Artery metabolism
- Abstract
Fetal growth restriction (FGR) is defined as the inability of a fetus to achieve its genetic growth potential and is associated with a significantly increased risk of morbidity and mortality. Clinically, FGR is diagnosed as a fetus falling below the 5(th) centile of customised growth charts. Sildenafil citrate (SC, Viagra™), a potent and selective phosphodiesterase-5 inhibitor, corrects ex vivo placental vascular dysfunction in FGR, demonstrating potential as a therapy for this condition. However, many FGR cases present without an abnormal vascular phenotype, as assessed by Doppler measures of uterine/umbilical artery blood flow velocity. Thus, we hypothesized that SC would not increase fetal growth in a mouse model of FGR, the placental-specific Igf2 knockout mouse, which has altered placental exchange capacity but normal placental blood flow. Fetal weights were increased (by 8%) in P0 mice following maternal SC treatment (0.4 mg/ml) via drinking water. There was also a trend towards increased placental weight in treated P0 mice (P = 0.056). Additionally, 75% of the P0 fetal weights were below the 5(th) centile, the criterion used to define human FGR, of the non-treated WT fetal weights; this was reduced to 51% when dams were treated with SC. Umbilical artery and vein blood flow velocity measures confirmed the lack of an abnormal vascular phenotype in the P0 mouse; and were unaffected by SC treatment. (14)C-methylaminoisobutyric acid transfer (measured to assess effects on placental nutrient transporter activity) per g placenta was unaffected by SC, versus untreated, though total transfer was increased, commensurate with the trend towards larger placentas in this group. These data suggest that SC may improve fetal growth even in the absence of an abnormal placental blood flow, potentially affording use in multiple sub-populations of individuals presenting with FGR.
- Published
- 2013
- Full Text
- View/download PDF
17. Ex vivo modeling of chemical synergy in prenatal kidney cystogenesis.
- Author
-
Anders C, Ashton N, Ranjzad P, Dilworth MR, and Woolf AS
- Subjects
- 8-Bromo Cyclic Adenosine Monophosphate adverse effects, 8-Bromo Cyclic Adenosine Monophosphate pharmacology, Animals, Dexamethasone adverse effects, Dexamethasone pharmacology, Female, Fetus pathology, Glucocorticoids adverse effects, Glucocorticoids pharmacology, Kidney pathology, Male, Mice, Polycystic Kidney Diseases chemically induced, Polycystic Kidney Diseases pathology, Pregnancy, Fetus embryology, Kidney embryology, Models, Biological, Polycystic Kidney Diseases embryology
- Abstract
Cyclic adenosine monophosphate (cAMP) drives genetic polycystic kidney disease (PKD) cystogenesis. Yet within certain PKD families, striking differences in disease severity exist between affected individuals, and genomic and/or environmental modifying factors have been evoked to explain these observations. We hypothesized that PKD cystogenesis is accentuated by an aberrant fetal milieu, specifically by glucocorticoids. The extent and nature of cystogenesis was assessed in explanted wild-type mouse embryonic metanephroi, using 8-Br-cAMP as a chemical to mimic genetic PKD and the glucocorticoid dexamethasone as the environmental modulator. Cysts and glomeruli were quantified by an observer blinded to culture conditions, and tubules were phenotyped using specific markers. Dexamethasone or 8-Br-cAMP applied on their own produced cysts predominantly arising in proximal tubules and descending limbs of loops of Henle. When applied together, however, dexamethasone over a wide concentration range synergized with 8-Br-cAMP to generate a more severe, glomerulocystic, phenotype; we note that prominent glomerular cysts have been reported in autosomal dominant PKD fetal kidneys. Our data support the idea that an adverse antenatal environment exacerbates renal cystogenesis.
- Published
- 2013
- Full Text
- View/download PDF
18. Effect of the anti-oxidant tempol on fetal growth in a mouse model of fetal growth restriction.
- Author
-
Stanley JL, Andersson IJ, Hirt CJ, Moore L, Dilworth MR, Chade AR, Sibley CP, Davidge ST, and Baker PN
- Subjects
- Amino Acid Transport System A metabolism, Animals, Biomimetic Materials pharmacology, Blood Flow Velocity drug effects, Disease Models, Animal, Female, Fetal Development drug effects, Fetal Development physiology, Fetal Growth Retardation pathology, Fetal Growth Retardation physiopathology, Humans, Mice, Mice, Inbred C57BL, Mice, Knockout, Nitric Oxide Synthase Type III deficiency, Nitric Oxide Synthase Type III genetics, Oxidative Stress drug effects, Placenta blood supply, Placenta drug effects, Placenta pathology, Placenta physiopathology, Pregnancy, Spin Labels, Superoxide Dismutase metabolism, Uterine Artery drug effects, Uterine Artery physiopathology, Antioxidants pharmacology, Cyclic N-Oxides pharmacology, Fetal Growth Retardation drug therapy
- Abstract
Fetal growth restriction (FGR) greatly increases the risk of perinatal morbidity and mortality and is associated with increased uterine artery resistance and levels of oxidative stress. There are currently no available treatments for this condition. The hypothesis that the antioxidant 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-oxyl (Tempol) would improve uterine artery function and rescue fetal growth was tested in a mouse model of FGR, using the endothelial nitric oxide synthase knockout mouse (Nos3(-/-)). Pregnant Nos3(-/-) and control C57BL/6J mice were treated with the superoxide dismutase-mimetic Tempol (1 mmol/L) or vehicle from Gestational Day 12.5 to 18.5. Tempol treatment significantly increased pup weight (P < 0.05) and crown-rump length (P < 0.01) in C57BL/6J and Nos3(-/-) mice. Uterine artery resistance was increased in Nos3(-/-) mice (P < 0.05); Tempol significantly increased end diastolic velocity in Nos3(-/-) mice (P < 0.05). Superoxide production in uterine arteries did not differ between C57BL/6J and Nos3(-/-) mice but was significantly increased in placentas from Nos3(-/-) mice (P < 0.05). This was not reduced by Tempol treatment. Placental System A activity was reduced in Nos3(-/-) mice (P < 0.01); this was not improved by treatment with Tempol. Treatment of Nos3(-/-) mice with Tempol, however, was associated with reduced vascular density in the placental bed (P < 0.05). This study demonstrated that treatment with the antioxidant Tempol is able to improve fetal growth in a mouse model of FGR. This was associated with an increase in uterine artery blood flow velocity but not an improvement in uterine artery function or placental System A activity.
- Published
- 2012
- Full Text
- View/download PDF
19. eNOS knockout mouse as a model of fetal growth restriction with an impaired uterine artery function and placental transport phenotype.
- Author
-
Kusinski LC, Stanley JL, Dilworth MR, Hirt CJ, Andersson IJ, Renshall LJ, Baker BC, Baker PN, Sibley CP, Wareing M, and Glazier JD
- Subjects
- Amino Acid Transport System A metabolism, Animals, Biological Transport physiology, Blood Pressure physiology, Female, Fetal Growth Retardation metabolism, Fetal Weight physiology, Mice, Mice, Inbred C57BL, Mice, Knockout, Nitric Oxide Synthase Type III genetics, Placenta metabolism, Pregnancy, Proteinuria metabolism, Proteinuria physiopathology, Superoxides metabolism, Fetal Growth Retardation physiopathology, Models, Animal, Nitric Oxide Synthase Type III deficiency, Phenotype, Placenta physiopathology, Uterine Artery physiopathology
- Abstract
Fetal growth restriction (FGR) is the inability of a fetus to reach its genetically predetermined growth potential. In the absence of a genetic anomaly or maternal undernutrition, FGR is attributable to "placental insufficiency": inappropriate maternal/fetal blood flow, reduced nutrient transport or morphological abnormalities of the placenta (e.g., altered barrier thickness). It is not known whether these diverse factors act singly, or in combination, having additive effects that may lead to greater FGR severity. We suggest that multiplicity of such dysfunction might underlie the diverse FGR phenotypes seen in humans. Pregnant endothelial nitric oxide synthase knockout (eNOS(-/-)) dams exhibit dysregulated vascular adaptations to pregnancy, and eNOS(-/-) fetuses of such dams display FGR. We investigated the hypothesis that both altered vascular function and placental nutrient transport contribute to the FGR phenotype. eNOS(-/-) dams were hypertensive prior to and during pregnancy and at embryonic day (E) 18.5 were proteinuric. Isolated uterine artery constriction was significantly increased, and endothelium-dependent relaxation significantly reduced, compared with wild-type (WT) mice. eNOS(-/-) fetal weight and abdominal circumference were significantly reduced compared with WT. Unidirectional maternofetal (14)C-methylaminoisobutyric acid (MeAIB) clearance and sodium-dependent (14)C-MeAIB uptake into mouse placental vesicles were both significantly lower in eNOS(-/-) fetuses, indicating diminished placental nutrient transport. eNOS(-/-) mouse placentas demonstrated increased hypoxia at E17.5, with elevated superoxide compared with WT. We propose that aberrant uterine artery reactivity in eNOS(-/-) mice promotes placental hypoxia with free radical formation, reducing placental nutrient transport capacity and fetal growth. We further postulate that this mouse model demonstrates "uteroplacental hypoxia," providing a new framework for understanding the etiology of FGR in human pregnancy.
- Published
- 2012
- Full Text
- View/download PDF
20. Placental-specific Igf2 knockout mice exhibit hypocalcemia and adaptive changes in placental calcium transport.
- Author
-
Dilworth MR, Kusinski LC, Cowley E, Ward BS, Husain SM, Constância M, Sibley CP, and Glazier JD
- Subjects
- Animals, Disease Models, Animal, Female, Fetal Growth Retardation genetics, Hypocalcemia genetics, Insulin-Like Growth Factor II genetics, Ion Transport, Male, Mice, Mice, Inbred C57BL, Mice, Knockout, Pregnancy, Calcium metabolism, Fetal Growth Retardation metabolism, Fetus metabolism, Hypocalcemia metabolism, Maternal-Fetal Exchange, Placenta metabolism
- Abstract
Evidence is emerging that the ability of the placenta to supply nutrients to the developing fetus adapts according to fetal demand. To examine this adaptation further, we tested the hypothesis that placental maternofetal transport of calcium adapts according to fetal calcium requirements. We used a mouse model of fetal growth restriction, the placental-specific Igf2 knockout (P0) mouse, shown previously to transiently adapt placental System-A amino acid transporter activity relative to fetal growth. Fetal and placental weights in P0 mice were reduced when compared with WT at both embryonic day 17 (E17) and E19. Ionized calcium concentration [Ca(2+)] was significantly lower in P0 fetal blood compared with both WT and maternal blood at E17 and E19, reflecting a reversal of the fetomaternal [Ca(2+)] gradient. Fetal calcium content was reduced in P0 mice at E17 but not at E19. Unidirectional maternofetal calcium clearance ((Ca) K (mf)) was not different between WT and P0 at E17 but increased in P0 at E19. Expression of the intracellular calcium-binding protein calbindin-D(9K), previously shown to be rate-limiting for calcium transport, was increased in P0 relative to WT placentas between E17 and E19. These data show an increased placental transport of calcium from E17 to E19 in P0 compared to WT. We suggest that this is an adaptation in response to the reduced fetal calcium accumulation earlier in gestation and speculate that the ability of the placenta to adapt its supply capacity according to fetal demand may stretch across other essential nutrients.
- Published
- 2010
- Full Text
- View/download PDF
21. Increased maternofetal calcium flux in parathyroid hormone-related protein-null mice.
- Author
-
Bond H, Dilworth MR, Baker B, Cowley E, Requena Jimenez A, Boyd RD, Husain SM, Ward BS, Sibley CP, and Glazier JD
- Subjects
- Animals, Biological Transport physiology, Calbindins, Female, Fetus metabolism, Homeostasis physiology, Male, Mice, Mice, Knockout, Parathyroid Hormone-Related Protein genetics, Placenta metabolism, Placental Circulation physiology, Pregnancy, S100 Calcium Binding Protein G metabolism, Calcium metabolism, Maternal-Fetal Exchange physiology, Parathyroid Hormone-Related Protein metabolism, Pregnancy, Animal metabolism
- Abstract
The role of parathyroid hormone-related protein (PTHrP) in fetal calcium homeostasis and placental calcium transport was examined in mice homozygous for the deletion of the PTHrP gene (PTHrP-/- null; NL) compared to PTHrP+/+ (wild-type; WT) and PTHrP+/- (heterozygous; HZ) littermates. Fetal blood ionized calcium was significantly reduced in NL fetuses compared to WT and HZ groups at 18 days of pregnancy (dp) with abolition of the fetomaternal calcium gradient. In situ placental perfusion of the umbilical circulation at 18 dp was used to measure unidirectional clearance of (45)Ca across the placenta in maternofetal ((Ca)K(mf)) and fetoplacental ((Ca)K(fp)) directions; (Ca)K(fp) was < 5% of (Ca)K(mf) for all genotypes. At 18 dp, (Ca)K(mf) across perfused placenta and intact placenta ((Ca)K(mf(intact))) were similar and concordant with net calcium accretion rates in vivo. (Ca)K(mf) was significantly raised in NL fetuses compared to WT and HZ littermates. Calcium accretion was significantly elevated in NL fetuses by 19 dp. Placental calbindin-D(9K) expression in NL fetuses was marginally enhanced (P < 0.07) but expression of TRPV6/ECaC2 and plasma membrane Ca2+-ATPase (PMCA) isoforms 1 and 4 were unaltered. We conclude that PTHrP is an important regulator of fetal calcium homeostasis with its predominant effect being on unidirectional maternofetal transfer, probably mediated by modifying placental calbindin-D(9K) expression. In situ perfusion of mouse placenta is a robust methodology for allowing detailed dissection of placental transfer mechanisms in genetically modified mice.
- Published
- 2008
- Full Text
- View/download PDF
22. Development and functional capacity of transplanted rat metanephroi.
- Author
-
Dilworth MR, Clancy MJ, Marshall D, Bravery CA, Brenchley PE, and Ashton N
- Subjects
- Actins metabolism, Animals, Aquaporins metabolism, Epithelial Sodium Channels metabolism, Female, Glomerular Filtration Rate physiology, Kidney blood supply, Male, Platelet Endothelial Cell Adhesion Molecule-1 metabolism, Pregnancy, RNA, Messenger metabolism, Rats, Rats, Inbred Lew, Receptor, Angiotensin, Type 2 metabolism, Regional Blood Flow physiology, Sodium-Potassium-Chloride Symporters metabolism, Vascular Resistance physiology, Kidney embryology, Kidney physiology, Kidney Transplantation physiology
- Abstract
Background: Transplantation of embryonic kidneys (metanephroi) offers a potential solution to the problem of kidney donor shortage. The aim of this study was to characterise the haemodynamic capacity of transplanted rat metanephroi and to determine the number and maturity of the tubules., Methods: Metanephroi from E15 Lewis rat embryos were transplanted adjacent to the abdominal aorta of uninephrectomised adult female syngeneic Lewis rats. Twenty-one days later, a single metanephros ureter was anastomosed to the host's urinary system. Three months later animals were prepared for standard clearance measurements., Results: Effective renal blood flow (149 +/- 33 microl min(-1) per g kidney weight) and glomerular filtration rate (17 +/- 9 microl min(-1) per g kidney weight), standardised to kidney weight, were significantly lower in transplanted metanephroi compared with control adult kidneys (P < 0.001); renal vascular resistance (934 +/- 209 mmHg ml min(-1) per g kidney weight) was significantly higher (P < 0.001). Nephron number in transplanted metanephroi was significantly greater than that of E21 kidneys (P < 0.01) but lower than that of postnatal day (PND) 1 kidneys (P < 0.001). Angiotensin II type 2 receptor mRNA expression, a marker of nephrogenesis, was markedly reduced in metanephroi. Aquaporins 1 and 2, epithelial Na channel and Na-K-2Cl cotransporter type 2 mRNA and protein were expressed in transplanted metanephroi; the urea transporters-A1, 2 and 3 were absent. Vascular markers (alpha-smooth muscle actin and CD31) were identified in metanephroi but their expression did not differ from that of E21 and PND 1 kidneys., Conclusions: This study shows that metanephroi continue to develop post-transplantation but only reach a stage of development equivalent to that of a normal rat kidney at birth.
- Published
- 2008
- Full Text
- View/download PDF
23. Increasing renal mass improves survival in anephric rats following metanephros transplantation.
- Author
-
Marshall D, Dilworth MR, Clancy M, Bravery CA, and Ashton N
- Subjects
- Anastomosis, Surgical, Animals, Kaplan-Meier Estimate, Kidney physiology, Nephrectomy, Organogenesis, Peritoneum surgery, Potassium blood, Potassium urine, Rats, Rats, Inbred Lew, Sodium blood, Sodium urine, Time Factors, Urea blood, Urea urine, Ureter surgery, Urination, Fetal Tissue Transplantation methods, Graft Survival, Kidney embryology, Kidney surgery, Kidney Transplantation methods
- Abstract
Renal failure and end-stage renal disease are prevalent diseases associated with high levels of morbidity and mortality, the preferred treatment for which is kidney transplantation. However, the gulf between supply and demand for kidneys remains high and is growing every year. A potential alternative to the transplantation of mature adult kidneys is the transplantation of the developing renal primordium, the metanephros. It has been shown previously, in rodent models, that transplantation of a metanephros can provide renal function capable of prolonging survival in anephric animals. The aim of the present study was to determine whether increasing the mass of transplanted tissue can prolong survival further. Embryonic day 15 rat metanephroi were transplanted into the peritoneum of anaesthetized adult rat recipients. Twenty-one days later, the transplanted metanephroi were anastomosed to the recipient's urinary system, and 35 days following anastomosis the animal's native renal mass was removed. Survival times and composition of the excreted fluid were determined. Rats with single metanephros transplants survived 29 h longer than anephric controls (P < 0.001); animals with two metanephroi survived 44 h longer (P < 0.001). A dilute urine was formed, with low concentrations of sodium, potassium and urea; potassium and urea concentrations were elevated in terminal serum samples, but sodium concentration and osmolality were comparable to control values. These data show that survival time is proportional to the mass of functional renal tissue. While transplanted metanephroi cannot currently provide life-sustaining renal function, this approach may have therapeutic benefit in the future.
- Published
- 2007
- Full Text
- View/download PDF
24. Application of a very high-throughput digital imaging screen to evolve the enzyme galactose oxidase.
- Author
-
Delagrave S, Murphy DJ, Pruss JL, Maffia AM 3rd, Marrs BL, Bylina EJ, Coleman WJ, Grek CL, Dilworth MR, Yang MM, and Youvan DC
- Subjects
- Galactose Oxidase metabolism, Genomic Library, Kinetics, Methylgalactosides metabolism, Mutation, Directed Molecular Evolution methods, Galactose Oxidase genetics, Image Processing, Computer-Assisted
- Abstract
Directed evolution has become an important enabling technology for the development of new enzymes in the chemical and pharmaceutical industries. Some of the most interesting substrates for these enzymes, such as polymers, have poor solubility or form highly viscous solutions and are therefore refractory to traditional high-throughput screens used in directed evolution. We combined digital imaging spectroscopy and a new solid-phase screening method to screen enzyme variants on problematic substrates highly efficiently and show here that the specific activity of the enzyme galactose oxidase can be improved using this technology. One of the variants we isolated, containing the mutation C383S, showed a 16-fold increase in activity, due in part to a 3-fold improvement in K(m). The present methodology should be applicable to the evolution of numerous other enzymes, including polysaccharide-modifying enzymes that could be used for the large-scale synthesis of modified polymers with novel chemical properties.
- Published
- 2001
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.